Observational Study in Type 2 Diabetes Treated by an Intensive Insulin Treatment (ICT) Containing Once Daily Levemir® (Insulin Detemir)

• Status: Completed
• Trial end date: 2009-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This study is conducted in Europe. The aim of this observational study is to gain practical experience with once-daily Levemir administration in type 2 diabetes patients who were previously treated with Insulatard®, Humulin® N (NPH insulins) as basal insulin as part of their ICT under normal clinical practice conditions in Hungary.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novo Nordisk A/S
• Treatments: Insulin; Insulin Detemir; Insulin, Globin Zinc

Criteria

Inclusion Criteria:

• Type 2 diabetic subjects on intensive insulin treatment (ICT)

• Eligibility for once daily insulin detemir administration

• Informed consent obtained before any observation-related activities

Exclusion Criteria:

• Known or suspected allergy to insulin detemir

• Subjects previously enrolled in the observation

• Women who are pregnant, breast feeding or have the intention of becoming pregnant within 6 months.